Volume
Open
Day's Low
Day's High
52 Wk Low
52 Wk High
Bid
Ask
EPS
PE Ratio
Shares
Market Cap
Dividend
Ex-Div Date
Yield
Interested in Gold Updates?
Receive the latest updates on the gold and silver markets.
...
Health Technology » Biotechnology
| symbol | company | %chng | last | %short | avg$volume | |
|---|---|---|---|---|---|---|
| MRNA | Moderna, Inc. | 1.19% | 137.88 | 0.0% | $904.62m | |
| AMGN | Amgen, Inc. | 1.04% | 250.08 | 1.5% | $837.59m | |
| GILD | Gilead Sciences, Inc. | 0.49% | 64.15 | 1.0% | $544.64m | |
| VRTX | Vertex Pharmaceuticals, Inc. | 4.32% | 269.76 | 1.9% | $481.90m | |
| REGN | Regeneron Pharmaceuticals, Inc. | 3.67% | 685.42 | 2.6% | $437.60m | |
| ILMN | Illumina, Inc. | 0.82% | 245.48 | 3.3% | $316.36m | |
| NVAX | Novavax, Inc. | -1.27% | 52.74 | 75.7% | $303.59m | |
| BIIB | Biogen, Inc. | 0.49% | 200.63 | 1.8% | $241.23m | |
| BNTX | BioNTech SE | 0.30% | 163.49 | 0.0% | $227.09m | |
| SNSS | Sunesis Pharmaceuticals, Inc. | -0.47% | 2.10 | 0.7% | $146.80m | |
| EXAS | EXACT Sciences Corp. | -2.13% | 52.04 | 17.7% | $143.96m | |
| NKTX | Nkarta, Inc. | 0.71% | 12.76 | 0.0% | $99.97m | |
| TECH | Bio-Techne Corp. | -0.98% | 362.75 | 4.5% | $99.81m | |
| BMRN | BioMarin Pharmaceutical, Inc. | 1.29% | 80.75 | 4.2% | $99.68m | |
| TXG | 10X Genomics, Inc. | -1.75% | 49.28 | 0.0% | $99.51m |
Company Profile
CRISPR Therapeutics AG is a gene editing company, which is focused on developing transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 platform. Its CRISPR/Cas9 platform is a revolutionary gene editing technology that allows for precise, directed changes to genomic DNA. The firm offers a portfolio of therapeutic programs across a broad range of disease areas including hemoglobinopathies, oncology, regenerative medicine, and rare diseases. The company was founded by Rodger Novak, Emmanuelle Charpentier, Shaun Patrick Foy, Matthew Porteus, Daniel Anderson, Chad Cowan and Craig Mellow on October 31, 2013 and is headquartered in Zug, Switzerland.